Next generation drug connectivity mapping for acquiring therapeutic agents to differentially regulate myelination

作     者：Kasum Azim Andrea Domenico Rivera Arthur Morgan Butt Kasum Azim;Andrea Domenico Rivera;Arthur Morgan Butt

作者机构：Department of NeurologyMedical FacultyHeinrich-Heine-UniversityDüsseldorfGermany Institute of Biomedical and Biomolecular SciencesSchool of Pharmacy and Biomedical ScienceUniversity of PortsmouthSt Michael’s BuildingWhite Swan RoadPortsmouthUK Section of Human AnatomyDepartment of NeuroscienceUniversity of PaduaPaduaItaly 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2023年第18卷第4期

页      面：797-798页

核心收录：

学科分类：1002[医学-临床医学] 100204[医学-神经病学] 10[医学] 

主　　题：connectivity dollar therapeutic 

摘      要：The need for new therapeutic approaches:Conventional drug discovery is a lengthy and expensive process,taking decades and billions of dollars to get a drug from bench to *** of the costs incurred are at the pre-clinical stages,between drug design and synthesis to delineating the cellular“Mechanisms of Action(MoA).Notably,there is a very high risk of failure,and only a very small proportion of therapeutic agents reach later-phase clinical ***,drug repositioning has become a valuable strategy aimed at fast-tracking treatments into clinical use and improving the chances of therapeutic success.A novel addition to this approach is connectivity mapping,which defines cell-specific transcriptional responses to small molecules in disease-dependent *** commentary outlines how some of the latest innovations in connectivity mapping can be exploited for drug repurposing.